ArticleBiomimetics (Basel, Switzerland)2025
A Bionic Sensing Platform for Cell Separation: Simulation of a Dielectrophoretic Microfluidic Device That Leverages Dielectric Fingerprints.
Article in Biomimetics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers are diseases described by the irregular spread of cells that have developed invasive features, enabling them to invade adjacent tissues. The specific diagnosis and effective management of oncological treatments depend on the timely detection of circulating tumor cells (CTCs) in a patient's bloodstream. One of the most promising approaches to CTC separation from blood fractions involves the dielectrophoresis (DEP) technique. This research presents a new DEP-based bionic system designed for MDA-MB-231 breast cancer cell isolation from white blood cell (WBC) subtypes with a viable approach to cell viability. This work leverages the principle that every cell type possesses a unique dielectric fingerprint. This dielectrophoresis microfluidic device is designed to act as a scanner, reading these fingerprints to achieve a continuous, label-free separation of cancer cells from blood components with a high efficiency. In the proposed system that consists of three different stages, the first stage allows for separating B-lymphocytes and Monocytes from Granulocytes and MDA-MB-231 cells. The separation of B-lymphocytes from Monocytes occurs in the second step, while the last step concerns the separation of Granulocytes and MDA-MB-231 cells. In the analysis, x-y graphs of the electric potentials, velocity fields, pressure distributions, and cellular DEP forces applied to the cells, as well as the resulting particle paths, are provided. The model predicts that the system operates with a separation efficiency of nearly 92%. This work focuses on an investigation of the impact of electrode potentials, the velocity of cells, the number of electrodes, the width of the channel, and the output angles on enhancing the separation efficiency of particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.